View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 05, 2016
Document Entity Information [Abstract]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		113,880,241

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 51,425	$ 15,577
Receivables, less allowance for doubtful accounts of $51,314 and $59,689 as of June 30, 2016 and December 31, 2015, respectively	98,634	97,353
Inventory	32,446	42,983
Prepaid expenses and other current assets	16,509	27,772
Total current assets	199,014	183,685
Property and equipment, net	30,789	31,939
Goodwill	308,729	308,729
Intangible assets, net	3,512	5,128
Other non-current assets	1,203	1,161
Total assets	543,247	530,642
Current liabilities
Current portion of long-term debt	9,357	24,380
Accounts payable	48,887	65,077
Amounts due to plan sponsors	3,553	3,491
Accrued interest	6,706	6,898
Accrued expenses and other current liabilities	33,158	52,918
Total current liabilities	101,661	152,764
Long-term debt, net of current portion	390,102	393,741
Deferred taxes	589	236
Other non-current liabilities	1,655	1,861
Total liabilities	494,007	548,602
Stockholders’ deficit
Preferred stock, $.0001 par value; 4,175,000 shares authorized; no shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	0	0
Common stock, $.0001 par value; 125,000,000 shares authorized; 116,641,664 and 71,421,664 shares issued and 113,880,241 and 68,767,613 shares outstanding as of June 30, 2016 and December 31, 2015, respectively	12	8
Treasury stock, 2,761,423 and 2,654,051 shares, at cost, as of June 30, 2016 and December 31, 2015, respectively	(11,009)	(10,737)
Additional paid-in capital	612,603	531,764
Accumulated deficit	(619,683)	(601,913)
Total stockholders’ deficit	(18,077)	(80,878)
Total liabilities and stockholders’ deficit	543,247	530,642
Series A Preferred Stock
Current liabilities
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 and 635,822 shares outstanding as of June 30, 2016 and December 31, 2015, respectively; and, $2,459 and $69,702 liquidation preference as of June 30, 2016 and December 31, 2015, respectively	2,292	62,918
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of June 30, 2016; and $71,298 liquidation preference as of June 30, 2016	2,292	62,918
Series C Preferred Stock
Current liabilities
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 and 635,822 shares outstanding as of June 30, 2016 and December 31, 2015, respectively; and, $2,459 and $69,702 liquidation preference as of June 30, 2016 and December 31, 2015, respectively	65,025	0
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of June 30, 2016; and $71,298 liquidation preference as of June 30, 2016	$ 65,025	$ 0

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Allowance for doubtful accounts	$ (51,314,000)	$ (59,689,000)
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	4,175,000	4,175,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares, issued (in shares)	116,641,664	71,421,664
Common stock, shares, outstanding (in shares)	113,880,241	68,767,613
Treasury stock, shares (in shares)	2,761,423	2,654,051
Series A Preferred Stock
Convertible preferred stock series, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock series, liquidation preference	$ 2,459,000	$ 69,702,000
Convertible preferred stock series, shares authorized (in shares)	825,000	825,000
Convertible preferred stock series, shares issued (in shares)	21,645	635,822
Convertible preferred stock series, shares outstanding (in shares)	21,645	635,822
Series C Preferred Stock
Convertible preferred stock series, par value (in dollars per share)	$ 0.0001	$ 0
Convertible preferred stock series, liquidation preference	$ 71,298,000	$ 0
Convertible preferred stock series, shares authorized (in shares)	625,000	0
Convertible preferred stock series, shares issued (in shares)	614,177	0
Convertible preferred stock series, shares outstanding (in shares)	614,177	0

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net revenue	$ 232,462	$ 246,897	$ 470,924	$ 491,254
Cost of revenue (excluding depreciation expense)	168,298	182,079	342,528	361,481
Gross profit	64,164	64,818	128,396	129,773
Other operating expenses	40,619	43,314	80,277	84,929
Bad debt expense	4,279	15,165	11,870	23,511
General and administrative expenses	9,414	11,866	20,465	23,565
Impairment of goodwill	0	238,000	0	238,000
Restructuring, acquisition, integration, and other expenses, net	4,291	5,969	6,958	9,673
Depreciation and amortization expense	4,252	6,247	8,790	12,041
Interest expense, net	9,469	9,080	18,881	18,243
Gain on disposition of property and equipment	0	0	(939)	0
Loss from continuing operations, before income taxes	(8,160)	(264,823)	(17,906)	(280,189)
Income tax expense (benefit)	149	(19,921)	172	(17,993)
Loss from continuing operations, net of income taxes	(8,309)	(244,902)	(18,078)	(262,196)
Income (loss) from discontinued operations, net of income taxes	75	94	308	(2,285)
Net loss	(8,234)	(244,808)	(17,770)	(264,481)
Accrued dividends on preferred stock	(2,056)	(1,805)	(4,054)	(2,258)
Deemed dividends on preferred stock	(173)	(2,186)	(345)	(3,350)
Loss attributable to common stockholders	$ (10,463)	$ (248,799)	$ (22,169)	$ (270,089)
Loss per common share:
Loss from continuing operations, basic and diluted (in dollars per share)	$ (0.14)	$ (3.62)	$ (0.32)	$ (3.90)
Loss from discontinued operations, basic and diluted (in dollars per share)	0.00	0.00	0.00	(0.03)
Loss per common share, basic and diluted (in dollars per share)	$ (0.14)	$ (3.62)	$ (0.32)	$ (3.93)
Weighted average common shares outstanding
Weighted average number of common shares outstanding, basic and diluted (in shares)	73,186	68,698	70,978	68,668

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (17,770)	$ (264,481)
Less: income (loss) from discontinued operations, net of income taxes	308	(2,285)
Loss from continuing operations, net of income taxes	(18,078)	(262,196)
Adjustments to reconcile net loss from continuing operations, net of income taxes to net cash used in operating activities:
Depreciation and amortization	8,790	12,041
Impairment of goodwill	0	238,000
Amortization of deferred financing costs and debt discount	1,989	1,792
Change in fair value of contingent consideration	102	(72)
Change in deferred income taxes	352	(15,834)
Stock-based compensation expense	1,990	2,819
Gain on disposition of property and equipment	(939)	0
Changes in assets and liabilities:
Receivables, net of bad debt expense	(1,281)	7,933
Inventory	10,537	(5,149)
Prepaid expenses and other assets	322	(691)
Accounts payable	(16,190)	(12,728)
Amounts due to plan sponsors	62	(1,403)
Accrued interest	(192)	(148)
Accrued expenses and other liabilities	(3,140)	(8,530)
Net cash used in operating activities from continuing operations	(15,676)	(44,166)
Net cash used in operating activities from discontinued operations	(5,913)	(1,994)
Net cash used in operating activities	(21,589)	(46,160)
Cash flows from investing activities:
Purchases of property and equipment	(5,466)	(5,797)
Proceeds from sale of property and equipment	1,132	0
Net cash used in investing activities	(4,334)	(5,797)
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock and warrants, net of issuance costs	0	58,951
Deferred and other financing costs	0	(1,218)
Borrowings on revolving credit facility	45,000	129,163
Repayments on revolving credit facility	(60,000)	(134,163)
Principal payments of long-term debt	(6,274)	0
Repayments of capital leases	(129)	(345)
Proceeds from equity offering, net of $7,133 in offering costs	83,267	0
Other	(93)	2
Net cash provided by financing activities	61,771	52,390
Net change in cash and cash equivalents	35,848	433
Cash and cash equivalents - beginning of period	15,577	740
Cash and cash equivalents - end of period	51,425	1,173
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	17,325	18,391
Cash paid during the period for income taxes	229	515
DISCLOSURE OF NON-CASH TRANSACTIONS:
Capital lease obligations incurred to acquire property and equipment	$ 753	$ 0

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Statement of Cash Flows [Abstract]
Equity offering issuance costs	$ 7,133	$ 0

BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

BASIS OF PRESENTATION

These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2015 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission. These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.

The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2016 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016.

The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Reclassifications

With the sale of the PBM Services segment (the “PBM Business”) in 2015 all prior period financial statements have been reclassified to include the PBM Business as discontinued operations, along with other reclassifications, as further described in Note 1 in the Annual Report.

Collectability of Accounts Receivable

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):



	June 30, 2016							December 31, 2015
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	20,860	$	9,945	$	30,805		$	19,944	$	11,369	$	31,313
Commercial	86,977		18,755		105,732			94,477		20,213		114,690
Patient	6,754		6,657		13,411			5,014		6,025		11,039
Gross accounts receivable	$	114,591	$	35,357	149,948			$	119,435	$	37,607	157,042
Allowance for doubtful accounts					(51,314		)					(59,689		)
Net accounts receivable					$	98,634						$	97,353

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09—Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). ASU 2016-09 modifies the accounting for share-based payment awards, including income tax consequences, classification of awards as equity or liabilities, and classification on the statement of cash flows. The effective date for ASU 2016-09 is for annual periods beginning after December 15, 2016, and interim periods within those fiscal years. The Company is assessing the impact of this new standard on its financial statements.

In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

In July 2015, the FASB issued ASU 2015-11—Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). ASU 2015-11 requires that inventory be measured at the lower of cost and net realizable value, and is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently assessing the impact of this new standard on its financial statements.

In April 2015, the FASB issued ASU 2015-03—Interest—Imputation of Interest (Subtopic 835-20): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted ASU 2015-03 in the accompanying consolidated financial statements on a retrospective basis. As of June 30, 2016, we have $3.5 million and $10.7 million of deferred financing costs that were reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt. As of December 31, 2015, we had $3.3 million and $12.6 million of deferred financing costs that were reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt.

In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company is assessing the impact of this new standard on its financial statements and has not yet selected a transition method.

LOSS PER SHARE

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Loss Per Share

LOSS PER SHARE

The Company presents basic and diluted loss per share for its common stock, par value $0.0001 per share (“Common Stock”). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and convertible Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Preferred Stock are determined using the “if converted” method.

Each of the Company's Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Numerator:
Loss from continuing operations, net of income taxes	$	(8,309	)	$	(244,902	)	$	(18,078	)	$	(262,196	)
Income (loss) from discontinued operations, net of income taxes	75			94			308			(2,285		)
Net loss	$	(8,234	)	$	(244,808	)	$	(17,770	)	$	(264,481	)
Accrued dividends on preferred stock	(2,056		)	(1,805		)	(4,054		)	(2,258		)
Deemed dividend on preferred stock	(173		)	(2,186		)	(345		)	(3,350		)
Loss attributable to common stockholders	$	(10,463	)	$	(248,799	)	$	(22,169	)	$	(270,089	)

Denominator - Basic and Diluted:
Weighted average common shares outstanding	73,186			68,698			70,978			68,668

Loss per Common Share:
Loss from continuing operations, basic and diluted	$	(0.14	)	$	(3.62	)	$	(0.32	)	$	(3.90	)
Loss from discontinued operations, basic and diluted	—			—			—			(0.03		)
Loss per common share, basic and diluted	$	(0.14	)	$	(3.62	)	$	(0.32	)	$	(3.93	)

The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three months ended June 30, 2016 and 2015 excludes the effect of 14.0 million and 6.1 million shares, respectively, and the computation of the diluted shares for the six months ended June 30, 2016 and 2015 excludes the effect of 15.5 million and 5.6 million shares, respectively, issued in connection with the PIPE Transaction and the Rights Offering (see Note 3 - Stockholders’ Deficit), as well as stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.

STOCKHOLDERS' DEFICIT

6 Months Ended

Jun. 30, 2016

Equity [Abstract]

Stockholders' Deficit

STOCKHOLDERS’ DEFICIT

Securities Purchase Agreement

On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00 (the “PIPE Preferred Shares”), (b) 1,800,000 PIPE Class A warrants (the “Class A Warrants”), and (c) 1,800,000 PIPE Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the PIPE Preferred Shares is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

Series A, Series B, and Series C Convertible Preferred Stock

In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued 625,000 shares of Series A Preferred Stock at $100.00 per share. In connection with the Rights Offering (as defined below), the Company issued an additional 10,822 shares of Series A Preferred Stock at $100.00 per share. The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company as described in the Annual Report. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock as previously disclosed in the Annual Report. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum.

On June 10, 2016, in order to allow the shares of Common Stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the “Series B Exchange Agreement”) pursuant to which the PIPE Investors agreed:

i) to exchange 614,177 shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which have the same terms as the Series A Preferred Stock previously described in the Company’s prior public filings, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of Common Stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and

ii) to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve 3,600,000 shares of our Common Stock for the exercise of the PIPE Warrants.

On June 14, 2016, the Company entered into another Exchange Agreement (the “Series C Exchange Agreement”) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of Series C Preferred Stock.

Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange 614,177 shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the 11.5% per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified “Consolidated EBITDA” as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve 3,600,000 shares of Common Stock for the exercise of the PIPE Warrants.

As a result of the exchanges discussed above, there are currently (a) 21,645 shares of Series A Preferred Stock outstanding, of which 10,823 shares are owned by the PIPE Investors, (b) no shares of Series B Preferred Stock outstanding, and (c) 614,177 shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.

As of June 30, 2016, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $2.5 million and $71.3 million, respectively.

PIPE Warrants

In connection with the PIPE Transaction, the Company issued 1,800,000 Class A Warrants and 1,800,000 Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of the Class A Warrants and the Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

The Company entered into a registration rights agreement, as amended (the “Registration Rights Agreement”), with the PIPE Investors that, among other things and subject to certain exceptions, requires the Company, upon the request of the PIPE Investors, to register the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A Preferred Shares, the Series C Preferred Shares, or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, the costs incurred in connection with such registrations will be borne by the Company. As provided under the Registration Rights Agreement, the Company on April 1, 2016 filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), to register, among other things, the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A Preferred Shares.

Rights Offering

On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.

With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.

Carrying Value of Series A Preferred Stock

As of June 30, 2016, the following values were accreted as described above and recorded as a reduction of additional paid in capital in Stockholders’ Equity and a deemed dividend on the Statement of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2016. The following table sets forth the activity recorded during the six months ended June 30, 2016 related to the Series A Preferred Stock (in thousands) issued for both the PIPE Transactions and the Rights Offering.



Series A Preferred Stock carrying value at December 31, 2015	$	62,918
Exchange of shares - Series A to Series C	(60,776		)
Accretion of discount related to issuance costs	12
Dividends recorded through June 30, 2016¹	138
Series A Preferred Stock carrying value June 30, 2016	$	2,292

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Carrying Value of Series C Preferred Stock



Series C Preferred Stock carrying value at 12/31/2015	$	—
Exchange of shares - Series A to Series C	60,776
Accretion of discount related to issuance costs	333
Dividends recorded through June 30, 2016¹	3,916
Series C Preferred Stock carrying value June 30, 2016	$	65,025

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Shelf Registration Statement

The Company filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the “2016 Shelf”). Under the 2016 Shelf at the time of effectiveness, the Company had the ability to raise up to $200.0 million, in one or more transactions, by selling Common Stock, preferred stock, debt securities, warrants, units and rights.

2016 Equity Offering

On June 22, 2016 we completed an underwritten public offering of 45,200,000 shares of our Common Stock, including 5,200,000 shares of Common Stock issued upon the underwriters’ full exercise of the over-allotment option, at a public offering price of $2.00 per share, less underwriting discounts and commissions and offering expenses payable by us (the “2016 Equity Offering”). We received net proceeds of approximately $83.3 million from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering expenses.

A portion of the net proceeds from the 2016 Equity Offering was used to temporarily repay our outstanding borrowings under the Revolving Credit Facility. We intend to draw from the Revolving Credit Facility and use the remainder of the 2016 Equity Offering net proceeds to fund the Cash Consideration (as defined below) and pay fees and expenses in connection with the pending Home Solutions Transaction (see below).

Pending Home Solutions Transaction

On June 11, 2016, we entered into an Asset Purchase Agreement (as amended by the First Amendment (as defined below), the “Home Solutions Agreement”), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the “First Amendment”), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. Home Solutions is a privately held company that is a provider of home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions.

Under the Home Solutions Agreement, we will acquire substantially all of the assets and assume certain liabilities of Home Solutions and its subsidiaries (the “Home Solutions Transaction”) for the Transaction Consideration (as defined below). Under the Home Solutions Agreement, we will not purchase, among other things, (a) any accounts receivable associated with governmental payors, (b) cash assets, (c) certain non-transferable assets (e.g., state licenses and Medicare and Medicaid certifications and personnel and employment records), (d) the equity of Home Solutions and its subsidiaries; (e) certain tax assets, (f) causes of actions related to any of the items specified as excluded assets or excluded liabilities in the Home Solutions Agreement, (g) any privileged materials, documents or records of Home Solutions related to such excluded assets or excluded liabilities, or (h) intercompany receivables.

The terms of the Home Solutions Agreement as modified by the First Amendment are set forth below. Subject to certain net working capital adjustments, the consideration for the Home Solutions Transaction (the “Transaction Consideration”) consists of: (i) $67.5 million in cash (the “Cash Consideration”); (ii) 3,750,000 shares of our Common Stock to be issued at closing (the “Transaction Closing Equity Consideration”); and (iii) contingent equity securities of the Company, in the form of restricted shares of our Common Stock (“RSUs”), issued in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the “Contingent Shares”). Upon issuance the RSUs will have no value, but will be reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration rights that require us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder’s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act.

We will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $4.00 per share or above over 20 consecutive trading days during the period beginning on the closing date of the Home Solutions Transaction and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $4.00 per share. We will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $5.00 per share or above over 20 consecutive trading days during the period beginning on the closing date of the Home Solutions Transaction and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $5.00 per share. The aggregate number of RSUs in Tranche A will be approximately 3.1 million and the aggregate number of RSUs in Tranche B will be 4.0 million. The maximum amount of Common Stock issuable in connection with the Home Solutions Transaction represents approximately 9.5% of our outstanding Common Stock, based on the number of outstanding shares as of June 30, 2016, assuming all the RSUs vest.

The Cash Consideration and the Transaction Closing Equity Consideration will be paid at closing, subject to customary closing adjustments. We plan to fund the Cash Consideration with cash on-hand and borrowings from our Revolving Credit Facility.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

DISCONTINUED OPERATIONS

6 Months Ended

Jun. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

Sale of PBM Services

On August 27, 2015, the Company completed the sale of substantially all of the Company’s PBM Services segment (as defined above, the “PBM Business”) pursuant to an Asset Purchase Agreement dated as of August 9, 2015 (the “Asset Purchase Agreement”), by and among the Company, BioScrip PBM Services, LLC and ProCare Pharmacy Benefit Manager Inc. (the “PBM Buyer”). Under the Asset Purchase Agreement, the PBM Buyer agreed to acquire substantially all of the assets used solely in connection with the PBM Business and to assume certain PBM Business liabilities (the “PBM Sale”). On the Closing Date, pursuant to the terms of the Asset Purchase Agreement, the Company received total cash consideration of approximately $24.6 million, including an adjustment for estimated Closing Date net working capital. On October 20, 2015, the Company finalized working capital adjustment negotiations in relation to the PBM Sale whereby the Company agreed to repay approximately $1.0 million to the PBM Buyer. The Company used the net proceeds from the PBM Sale to pay down a portion of the Company’s outstanding debt.

The sale of the PBM Business was consistent with the Company’s continuing strategic evaluation of its non-core businesses and its decision to continue to focus growth initiatives and capital in the Infusion Services business. As a result, the Company has reclassified its operations to discontinued operations for all prior periods in the accompanying Unaudited Consolidated Financial Statements.

The operating results included in discontinued operations for the three months and six months ended June 30, 2016 and 2015 are summarized as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Revenue	$	—		$	15,466		$	—		$	32,790
Gross profit	$	—		$	3,722		$	—		$	7,358
Other operating expenses, net	(131		)	3,647			(514		)	9,689
Bad debt expense	—			(19		)	—			(46		)
Income (loss) before income taxes	131			94			514			(2,285		)
Income tax provision	56			—			206			—
Total income (loss) from discontinued operations, net of income taxes	$	75		$	94		$	308		$	(2,285	)

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET

6 Months Ended

Jun. 30, 2016

Restructuring and Related Activities [Abstract]

Restructuring, Acquisition, Integration, and Other Expenses, Net

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET

Restructuring, acquisition, integration and other expenses, net include costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed locations.

Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the three months and six months ended June 30, 2016 and 2015 consisted of the following (in thousands):



	Three Months Ended June 30,					Six Months Ended June 30,
	2016		2015			2016		2015
Restructuring expense	$	1,316	$	4,398		$	3,932	$	7,861
Acquisition and integration expense	2,924		1,664			2,924		1,884
Change in fair value of contingent consideration	51		(93		)	102		(72		)
Total restructuring, acquisition, integration, and other expense, net	$	4,291	$	5,969		$	6,958	$	9,673

On August 10, 2015, the Company announced a plan to implement a new operations financial improvement plan (the “Financial Improvement Plan”) as part of an initiative to accelerate long-term growth, reduce costs and increase operating efficiencies. In connection with the Financial Improvement Plan, the Company consolidated most corporate functions from our Eden Prairie, Minnesota corporate office and our Elmsford, New York executive office into our new executive and corporate office located in Denver, Colorado. The Financial Improvement Plan was substantially completed by the end of 2015.

DEBT

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Debt

DEBT

As of June 30, 2016 and December 31, 2015, the Company’s debt consisted of the following (in thousands):



	June 30, 2016			December 31, 2015
Revolving Credit Facility	$	—		$	15,000
Term Loan Facilities	216,481			222,757
2021 Notes, net of unamortized discount	196,347			196,038
Capital leases	812			189
Less: Deferred financing costs	(14,181		)	(15,863		)
Total Debt	399,459			418,121
Less: Current portion	9,357			24,380
Long-term debt, net of current portion	$	390,102		$	393,741

Senior Credit Facilities

The Company is obligated under (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank, Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc. (collectively, the “Lenders”), originally entered on July 31, 2013 and amended from time to time.

The applicable interest rates for each of the Term Loan Facilities is the Eurodollar rate plus 6.00% or the base rate plus 5.00%, until the occurrence of certain pricing decrease triggering events, as defined in the amended Senior Credit Facilities. Upon the occurrence of a pricing decrease triggering event, the interest rates for the Senior Credit Facilities may revert to the Eurodollar rate plus 5.25% or the base rate plus 4.25%. As of June 30, 2016, the interest rates related to the Revolving Credit Facility and the Term Loan Facilities are approximately 7.75% and 6.50%, respectively.

The Revolving Credit Facility matures on July 31, 2018 at which time all principal amounts outstanding are due and payable. The Term Loan Facilities require quarterly principal repayments of $3.1 million beginning March 31, 2016 until their July 31, 2020 maturity at which time the remaining principal amount of approximately $166.3 million is due and payable.

As of June 30, 2016, the Company had borrowing capacity of $70.4 million (borrowing capacity of $55.4 million to remain subject to an alternate leverage test) under its Revolving Credit Facility after considering outstanding letters of credit totaling $4.6 million.

2021 Notes

On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.

Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.

The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of June 30, 2016, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (in thousands):



Financial Instrument	Carrying Value as of June 30, 2016		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Term Loan Facilities	$	216,481	$	—	$	207,822	$	—
2021 Notes	196,347		—		181,130		—
Total	$	412,828	$	—	$	388,952	$	—

The fair value hierarchy for disclosure of fair value measurements is as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.

Level 3: Inputs that are unobservable for the assets or liabilities. Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings Breach of Contract Litigation in the Delaware Court of Chancery On November 3, 2015, Walgreen Co. and various affiliates (“Walgreens”) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the “Defendants”). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries (the “2012 Purchase Agreement”). The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the complaint, asserting, among other things, that the claims raised in Walgreens’ complaint were subject to the alternative dispute resolution procedure contained in the 2012 Purchase Agreement. On March 11, 2016, the Court held oral argument on the Company’s motion to dismiss and granted the motion, holding that Walgreens’ breach of contract claims for money damages must be resolved in accordance with the 2012 Purchase Agreement’s alternative dispute resolution procedure. On March 15, 2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court at that time, but instead would engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not grant Walgreens any other relief or enjoin the Company from taking any action. The Company continues to believe that Walgreens’ claims are without merit and intends to vigorously defend itself against them. Due to the inherent uncertainty in litigation, however, the Company can provide no assurance as to the outcome of the matter or reasonably estimate a range of possible loss at this time. Derivative Lawsuit in the Delaware Court of Chancery On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery by the Park Employees’ & Retirement Board Employees’ Annuity & Benefit Fund of Chicago (the “Derivative Complaint”). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the “Director Defendants”), certain former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the “Officer Defendants”), Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as Park Employees and Retirement Board Employees’ Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015). The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company’s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys’ fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from In re BioScrip, Inc., Securities Litigation (described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016. On May 31, 2016, the court determined that the Plaintiff’s claims could not proceed as pled but granted the Plaintiff thirty days in which to make a motion to amend the Derivative Complaint. The court reserved decision on the motion to dismiss and on June 29, 2016, the Plaintiff filed a motion for leave to file an amended complaint. The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources. Prior State Regulatory Matter The Company has previously accrued, and continues to carry, an estimate of a potential loss in connection with a pending regulatory and various other matters related to certain discontinued operations of the Company. The accrual recorded is not a material amount and represents the Company’s best estimate of the exposure. United States Attorney’s Office for the Southern District of New York and New York State Attorney General investigation Effective January 8, 2014, the Company entered into the Federal Settlement Agreement with the U.S. Department of Justice (the “DOJ”) and David M. Kester (the “Relator”). The Federal Settlement Agreement represented the federal and private component of the Company’s agreement to settle all civil claims under the False Claims Act and related statutes and all common law claims (collectively, the “Claims”) that could have been brought by the DOJ and Relator in the qui tam lawsuit filed in the Southern District of New York (the “SDNY”) by the Relator relating to the distribution of the Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) by the Company’s legacy specialty pharmacy division (the “Legacy Division”) that was divested in May 2012 (the “Civil Action”). Effective February 11, 2014, the Company entered into the State Settlement Agreements with the Settling States. The State Settlement Agreements represented the state component of the Company’s agreement to settle the Claims that could have been brought by the Settling States that arose out of the Legacy Division’s distribution of the Medication. With the execution of the Federal Settlement Agreement and the State Settlement Agreements (collectively, the “Settlement Agreements”), the Civil Action has been fully resolved, and the Company also expects to be fully resolved of the federal and state claims that were or could have been raised in the Civil Action. All federal claims and all state claims by the Settling States that have been or could be brought against it in the Civil Action have been dismissed with prejudice. The State Settlement Agreements expressly recognize and affirmatively provide that, by entering into the State Settlement Agreements, the Company has not made any admission of liability and the Company expressly denies the allegations in the Civil Action. Under the Settlement Agreements, the Company paid an aggregate of $15.0 million, plus interest (at an annual rate of 3.25%) in three annual payments from January 2014 through January 2016, of which the remaining $6.2 million, including interest, and $0.2 million of fees to the Relator was paid in January 2016. The Settlement Agreements represented a compromise to avoid the costs, distraction and uncertainty of protracted litigation. The Settlement Agreements do not include any admission of wrongdoing, illegal activity, or liability by the Company or its employees, directors, officers or agents. Securities Class Action Litigation in the Southern District of New York On September 30, 2013, a putative securities class action lawsuit was filed in the United States District Court for the Southern District of New York (“SDNY”) against the Company and certain of its officers on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 20, 2013, inclusive. On November 15, 2013, a putative securities class action lawsuit was filed in SDNY against the Company and certain of its directors and officers and certain underwriters in the Company’s April 2013 underwritten public offering of its common stock, on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 23, 2013, inclusive. On December 19, 2013, the SDNY entered an order consolidating the two class action lawsuits as In re BioScrip, Inc., Securities Litigation, No. 13-cv-6922 (AJN) and appointing an interim lead plaintiff. The Company denies any allegations of wrongdoing in the consolidated class action lawsuit. The lead plaintiff filed a consolidated complaint on February 19, 2014 against the Company, certain of its directors and officers, certain underwriters in the Company’s April 2013 underwritten public offering of its common stock, and a certain stockholder of the Company. The consolidated complaint is brought on behalf of a putative class of purchasers of the Company’s securities between November 9, 2012 and November 6, 2013, inclusive, and persons and entities who purchased the Company’s securities pursuant or traceable to two underwritten public offerings of the Company’s common stock conducted in April 2013, and August 2013. The consolidated complaint alleges generally that the defendants made material misstatements and/or failed to disclose matters related to the Legacy Division’s distribution of Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) as well as the Company’s PBM Services segment. The consolidated complaint asserts claims under Sections 11, 12(a)(2) and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. All defendants in the case moved to dismiss the consolidated complaint on April 28, 2014. On March 31, 2015, the SDNY granted in part and denied in part the defendants’ motions to dismiss. On September 25, 2015, the parties entered mediation concerning all pending claims. In October 2015, the parties reached an agreement in principle to settle all claims in the action (the “Proposed Settlement”), the terms and conditions of which were filed with the SDNY on December 18, 2015. The Company has agreed to the Proposed Settlement without any admission of liability or wrongdoing and solely in order to avoid the costs, distraction, and uncertainty of litigation. On February 11, 2016, the Court granted preliminary approval for the settlement, certified a class of plaintiffs for settlement only, approved of the form of and mailing of notice to the stockholder class, and scheduled a final fairness hearing for June 13, 2016. Following preliminary approval, in accordance with the terms of the Proposed Settlement, the Company and its insurance carriers paid the amount of the settlement into an escrow fund. The Company’s contribution was not material, and the Company does not believe the contribution will have a material effect on results of operations, financial position, liquidity or capital resources. On June 16, 2016, the Court granted final approval for the settlement. As a result, this case has now been dismissed with prejudice. Government Regulation Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company’s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted. From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Unaudited Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s Unaudited Consolidated Financial Statements.

CONCENTRATION OF RISK	6 Months Ended
CONCENTRATION OF RISK	Jun. 30, 2016
Risks and Uncertainties [Abstract]
Concentration of Risk	CONCENTRATION OF RISK Customer and Credit Risk The Company provides trade credit to its customers in the normal course of business. One commercial payor, United Healthcare, accounted for approximately 24.4% and 25.4% of revenue during the three months ended June 30, 2016 and 2015, respectively, and approximately 25.2% and 25.9% of revenue during the six months ended June 30, 2016 and 2015, respectively. In addition, Medicare accounted for approximately 11.2% and 10.4% of revenue during the three months ended June 30, 2016 and 2015, respectively, and approximately 10.7% and 10.8% of revenue during the six months ended June 30, 2016 and 2015, respectively. Therapy Revenue Risk The Company sells products related to the Immune Globulin therapy, which represented 17.2% and 16.0% of revenue for the three months ended June 30, 2016 and 2015, respectively, and 17.2% and 15.8% of revenue during the six months ended June 30, 2016 and 2015, respectively.

INCOME TAXES

6 Months Ended

Jun. 30, 2016

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company’s federal and state income tax expense (benefit) from continuing operations for the three months and six months ended June 30, 2016 and 2015 is summarized in the following table (in thousands):



	Three Months Ended June 30,					Six Months Ended June 30,
	2016		2015			2016		2015
Current
Federal	$	—	$	—		$	—	$	—
State	25		29			25		30
Total current	25		29			25		30
Deferred
Federal	108		(16,816		)	125		(15,188		)
State	16		(3,134		)	22		(2,835		)
Total deferred	124		(19,950		)	147		(18,023		)
Total income tax expense (benefit)	$	149	$	(19,921	)	$	172	$	(17,993	)

The income tax expense recognized for the three months and six months ended June 30, 2016 is a result of an increase in the deferred tax liability.

The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and six months ended June 30, 2016 and 2015 is summarized as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Tax benefit at statutory rate	$	(2,844	)	$	(92,080	)	$	(6,271	)	$	(96,972	)
State tax benefit, net of federal taxes	3			11			3			11
Valuation allowance changes affecting income tax provision	1,926			31,098			5,314			37,879
Goodwill impairment	—			40,977			—			40,977
Non-deductible transaction costs and other	1,064			73			1,126			112
Income tax expense (benefit)	$	149		$	(19,921	)	$	172		$	(17,993	)

At June 30, 2016, we had Federal net operating loss (“NOL”) carry forwards of approximately $274.9 million, of which $17.0 million is subject to an annual limitation, which will begin expiring in 2026 and later. Of our Federal NOLs, $18.0 million will be recorded in additional paid-in capital when realized. These NOLs are related to the exercise of non-qualified stock options and restricted stock grants. We have post-apportioned state NOL carry forwards of approximately $358.0 million, the majority of which will begin expiring in 2017 and later.

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION BioScrip Equity Incentive Plan Under the Company’s Amended and Restated 2008 Equity Incentive Plan (as amended and restated, the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights ("SARs"), restricted stock grants, restricted stock units and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. On May 8, 2014, the Company’s stockholders (i) approved an amendment to the 2008 Plan to increase the number of authorized shares of Common Stock available for issuance by 2,500,000 shares (the “2014 Additional Shares”) to 9,355,000 shares and to clarify that cash dividends or dividend equivalents may not be paid to holders of unvested restricted stock units, restricted stock grants and performance units until such awards are vested and non-forfeitable; and (ii) re-approved the material terms of the performance goals that are a part of the 2008 Plan. On September 19, 2014, the Company filed a Registration Statement on Form S-8 to register the issuance of the 2014 Additional Shares that were approved by the Company’s stockholders on May 8, 2014. As of June 30, 2016, 1,963,228 shares remain available for grant under the 2008 Plan. Stock Options The Company recognized compensation expense related to stock options of $0.7 million and $1.2 million during the three months ended June 30, 2016 and 2015, respectively, and $1.7 million and $3.1 million during the six months ended June 30, 2016 and 2015, respectively. Restricted Stock The Company recognized a nominal amount of compensation expense related to restricted stock awards during the three months ended June 30, 2016 and $0.1 million of compensation expense related to restricted stock awards during the three months ended June 30, 2015. In addition, the Company recognized a nominal amount of compensation expense related to restricted stock awards during the six months ended June 30, 2016 and $0.3 million of compensation expense related to restricted stock awards during the six months ended June 30, 2015. Stock Appreciation Rights and Market Based Cash Awards The Company recognized a nominal amount of compensation expense related to stock appreciation rights awards during the three months ended June 30, 2016 and $0.1 million of compensation benefit related to stock appreciation rights awards during the three months ended June 30, 2015. The Company recognized $0.1 million of compensation expense and $0.6 million of compensation benefit related to stock appreciation rights awards during the six months ended June 30, 2016 and 2015, respectively. In addition, the Company recognized $0.2 million compensation benefit and nominal compensation expense related to market based cash awards during the three months ended June 30, 2016 and 2015, respectively, and $0.1 million compensation expense and nominal compensation expense during six months ended June 30, 2016 and 2015, respectively. Employee Stock Purchase Plan On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company has filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP. As of June 30, 2016, there were 461,057 shares that remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 288,943 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three and six months ended June 30, 2016 and 2015, less than $0.1 million of expense was incurred related to the ESPP.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

BASIS OF PRESENTATION (Policies)	6 Months Ended
BASIS OF PRESENTATION (Policies)	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2015 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission. These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2016 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016.
Consolidation	The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09—Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). ASU 2016-09 modifies the accounting for share-based payment awards, including income tax consequences, classification of awards as equity or liabilities, and classification on the statement of cash flows. The effective date for ASU 2016-09 is for annual periods beginning after December 15, 2016, and interim periods within those fiscal years. The Company is assessing the impact of this new standard on its financial statements. In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11—Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). ASU 2015-11 requires that inventory be measured at the lower of cost and net realizable value, and is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently assessing the impact of this new standard on its financial statements. In April 2015, the FASB issued ASU 2015-03—Interest—Imputation of Interest (Subtopic 835-20): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted ASU 2015-03 in the accompanying consolidated financial statements on a retrospective basis. As of June 30, 2016, we have $3.5 million and $10.7 million of deferred financing costs that were reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt. As of December 31, 2015, we had $3.3 million and $12.6 million of deferred financing costs that were reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt. In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company is assessing the impact of this new standard on its financial statements and has not yet selected a transition method.

BASIS OF PRESENTATION (Tables)

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Accounts Receivable Aging



	June 30, 2016							December 31, 2015
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	20,860	$	9,945	$	30,805		$	19,944	$	11,369	$	31,313
Commercial	86,977		18,755		105,732			94,477		20,213		114,690
Patient	6,754		6,657		13,411			5,014		6,025		11,039
Gross accounts receivable	$	114,591	$	35,357	149,948			$	119,435	$	37,607	157,042
Allowance for doubtful accounts					(51,314		)					(59,689		)
Net accounts receivable					$	98,634						$	97,353

LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Numerator:
Loss from continuing operations, net of income taxes	$	(8,309	)	$	(244,902	)	$	(18,078	)	$	(262,196	)
Income (loss) from discontinued operations, net of income taxes	75			94			308			(2,285		)
Net loss	$	(8,234	)	$	(244,808	)	$	(17,770	)	$	(264,481	)
Accrued dividends on preferred stock	(2,056		)	(1,805		)	(4,054		)	(2,258		)
Deemed dividend on preferred stock	(173		)	(2,186		)	(345		)	(3,350		)
Loss attributable to common stockholders	$	(10,463	)	$	(248,799	)	$	(22,169	)	$	(270,089	)

Denominator - Basic and Diluted:
Weighted average common shares outstanding	73,186			68,698			70,978			68,668

Loss per Common Share:
Loss from continuing operations, basic and diluted	$	(0.14	)	$	(3.62	)	$	(0.32	)	$	(3.90	)
Loss from discontinued operations, basic and diluted	—			—			—			(0.03		)
Loss per common share, basic and diluted	$	(0.14	)	$	(3.62	)	$	(0.32	)	$	(3.93	)

STOCKHOLDERS' DEFICIT (Tables)

6 Months Ended

Jun. 30, 2016

Equity [Abstract]

Carrying value and activity of Preferred Shares

The following table sets forth the activity recorded during the six months ended June 30, 2016 related to the Series C Preferred Stock (in thousands).



Series C Preferred Stock carrying value at 12/31/2015	$	—
Exchange of shares - Series A to Series C	60,776
Accretion of discount related to issuance costs	333
Dividends recorded through June 30, 2016¹	3,916
Series C Preferred Stock carrying value June 30, 2016	$	65,025

The following table sets forth the activity recorded during the six months ended June 30, 2016 related to the Series A Preferred Stock (in thousands) issued for both the PIPE Transactions and the Rights Offering.



Series A Preferred Stock carrying value at December 31, 2015	$	62,918
Exchange of shares - Series A to Series C	(60,776		)
Accretion of discount related to issuance costs	12
Dividends recorded through June 30, 2016¹	138
Series A Preferred Stock carrying value June 30, 2016	$	2,292

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

DISCONTINUED OPERATIONS (Tables)

6 Months Ended

Jun. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Operating Results of Discontinued Operations

The operating results included in discontinued operations for the three months and six months ended June 30, 2016 and 2015 are summarized as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Revenue	$	—		$	15,466		$	—		$	32,790
Gross profit	$	—		$	3,722		$	—		$	7,358
Other operating expenses, net	(131		)	3,647			(514		)	9,689
Bad debt expense	—			(19		)	—			(46		)
Income (loss) before income taxes	131			94			514			(2,285		)
Income tax provision	56			—			206			—
Total income (loss) from discontinued operations, net of income taxes	$	75		$	94		$	308		$	(2,285	)

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET (Tables)

6 Months Ended

Jun. 30, 2016

Restructuring and Related Activities [Abstract]

Schedule of restructuring, acquisition, integration, and other expenses, net



	Three Months Ended June 30,					Six Months Ended June 30,
	2016		2015			2016		2015
Restructuring expense	$	1,316	$	4,398		$	3,932	$	7,861
Acquisition and integration expense	2,924		1,664			2,924		1,884
Change in fair value of contingent consideration	51		(93		)	102		(72		)
Total restructuring, acquisition, integration, and other expense, net	$	4,291	$	5,969		$	6,958	$	9,673

DEBT (Tables)

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Summary of Long-term Debt

As of June 30, 2016 and December 31, 2015, the Company’s debt consisted of the following (in thousands):



	June 30, 2016			December 31, 2015
Revolving Credit Facility	$	—		$	15,000
Term Loan Facilities	216,481			222,757
2021 Notes, net of unamortized discount	196,347			196,038
Capital leases	812			189
Less: Deferred financing costs	(14,181		)	(15,863		)
Total Debt	399,459			418,121
Less: Current portion	9,357			24,380
Long-term debt, net of current portion	$	390,102		$	393,741

Schedule of Carrying and Estimated Fair Values of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (in thousands):



Financial Instrument	Carrying Value as of June 30, 2016		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Term Loan Facilities	$	216,481	$	—	$	207,822	$	—
2021 Notes	196,347		—		181,130		—
Total	$	412,828	$	—	$	388,952	$	—

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2016

Income Tax Disclosure [Abstract]

Schedule of Federal and State Income Tax Provision



	Three Months Ended June 30,					Six Months Ended June 30,
	2016		2015			2016		2015
Current
Federal	$	—	$	—		$	—	$	—
State	25		29			25		30
Total current	25		29			25		30
Deferred
Federal	108		(16,816		)	125		(15,188		)
State	16		(3,134		)	22		(2,835		)
Total deferred	124		(19,950		)	147		(18,023		)
Total income tax expense (benefit)	$	149	$	(19,921	)	$	172	$	(17,993	)

Reconciliation of the Income Tax Rate



	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Tax benefit at statutory rate	$	(2,844	)	$	(92,080	)	$	(6,271	)	$	(96,972	)
State tax benefit, net of federal taxes	3			11			3			11
Valuation allowance changes affecting income tax provision	1,926			31,098			5,314			37,879
Goodwill impairment	—			40,977			—			40,977
Non-deductible transaction costs and other	1,064			73			1,126			112
Income tax expense (benefit)	$	149		$	(19,921	)	$	172		$	(17,993	)

BASIS OF PRESENTATION - Accounts Receivable Aging (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	$ 149,948	$ 157,042
Allowance for doubtful accounts	(51,314)	(59,689)
Net accounts receivable	98,634	97,353
Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	30,805	31,313
Commercial
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	105,732	114,690
Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	13,411	11,039
Receivables 0 to 180 Days Past Due
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	114,591	119,435
Receivables 0 to 180 Days Past Due \| Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	20,860	19,944
Receivables 0 to 180 Days Past Due \| Commercial
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	86,977	94,477
Receivables 0 to 180 Days Past Due \| Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	6,754	5,014
Receivables Over 180 Days Past Due
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	35,357	37,607
Receivables Over 180 Days Past Due \| Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	9,945	11,369
Receivables Over 180 Days Past Due \| Commercial
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	18,755	20,213
Receivables Over 180 Days Past Due \| Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	$ 6,657	$ 6,025

BASIS OF PRESENTATION - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	$ 14,181	$ 15,863
Accounting Standards Update 2015-03 \| Current Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	(3,500)	(3,300)
Accounting Standards Update 2015-03 \| Long-term Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	(10,700)	(12,600)
Accounting Standards Update 2015-03 \| Long-term Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	$ 14,200	$ 15,900

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Class of Stock [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001		$ 0.0001
Antidilutive securities excluded from computation of earnings per share (in shares)	14,000	6,100	15,500	5,600
Numerator:
Loss from continuing operations, net of income taxes	$ (8,309)	$ (244,902)	$ (18,078)	$ (262,196)
Income (loss) from discontinued operations, net of income taxes	75	94	308	(2,285)
Net loss	(8,234)	(244,808)	(17,770)	(264,481)
Accrued dividends on preferred stock	(2,056)	(1,805)	(4,054)	(2,258)
Deemed dividends on preferred stock	(173)	(2,186)	(345)	(3,350)
Loss attributable to common stockholders	$ (10,463)	$ (248,799)	$ (22,169)	$ (270,089)
Denominator - Basic and Diluted:
Weighted average number of common shares outstanding, basic and diluted (in shares)	73,186	68,698	70,978	68,668
Loss per Common Share:
Loss from continuing operations, basic and diluted (in dollars per share)	$ (0.14)	$ (3.62)	$ (0.32)	$ (3.90)
Loss from discontinued operations, basic and diluted (in dollars per share)	0.00	0.00	0.00	(0.03)
Loss per common share, basic and diluted (in dollars per share)	(0.14)	$ (3.62)	(0.32)	$ (3.93)
Series A Preferred Stock
Class of Stock [Line Items]
Series A convertible preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001		$ 0.0001

STOCKHOLDERS' DEFICIT - Additional Information (Details) - USD ($)					6 Months Ended
	Jun. 22, 2016	Jun. 14, 2016	Jul. 27, 2015	Mar. 09, 2015	Jun. 30, 2016	May 02, 2016	Dec. 31, 2015	Jun. 30, 2015
Class of Warrant or Right [Line Items]
Amount of equity able to raise						$ 200,000,000
Proceeds from issuance of equity and temporary equity			$ 1,100,000	$ 62,500,000
Preferred stock, par value (in dollars per share)					$ 0.0001		$ 0.0001
Series A Preferred Stock
Class of Warrant or Right [Line Items]
Shares issued (in shares)			10,822	625,000	21,645		635,822
Convertible preferred stock series, shares outstanding (in shares)					21,645		635,822
Share price (in dollars per share)			$ 100	$ 100.00
Redemption price (in dollars per share)				$ 5.17
Series A convertible preferred stock, shares authorized (in shares)				825,000	825,000		825,000
Convertible preferred stock series, liquidation preference					$ 2,459,000		$ 69,702,000
Preferred stock, par value (in dollars per share)								$ 5.17
Dividend accrual rate					11.50%
Series B Preferred Stock
Class of Warrant or Right [Line Items]
Convertible preferred stock series, shares outstanding (in shares)					0
Shares converted (in shares)		614,177
Series C Preferred Stock
Class of Warrant or Right [Line Items]
Shares issued (in shares)					614,177		0
Convertible preferred stock series, shares outstanding (in shares)					614,177		0
Series A convertible preferred stock, shares authorized (in shares)					625,000		0
Convertible preferred stock series, liquidation preference					$ 71,298,000		$ 0
Dividend rate of non-cash dividend payable					11.50%
Shares issued in conversion (in shares)		614,177
PIPE Warrants
Class of Warrant or Right [Line Items]
Additional contribution by investors				$ 500,000
PIPE Warrants \| Series A Preferred Stock
Class of Warrant or Right [Line Items]
Shares issued (in shares)					10,823
PIPE Warrants \| Series C Preferred Stock \| Common Stock
Class of Warrant or Right [Line Items]
Common stock reserved for future issuance (in shares)					3,600,000
Class A Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)			31,025	1,800,000
Exercise price of warrants (in dollars per share)				$ 5.17				5.17
Class A Warrants Prior to Addendum
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)				$ 5.295
Class B Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)			31,025	1,800,000
Exercise price of warrants (in dollars per share)				$ 6.45				$ 6.45
Class B Warrants Prior to Addendum
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)				$ 6.595
Over-Allotment Option \| Common Stock
Class of Warrant or Right [Line Items]
Stock issued in secondary offering (in shares)	5,200,000
Secondary Offering \| Common Stock
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 2.00
Stock issued in secondary offering (in shares)	45,200,000
Value of stock issued in secondary offering	$ 83,300,000

STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning Balance	$ 62,918
Exchange of shares - Series A to Series C	(60,776)
Accretion of discount related to issuance costs	12
Dividends recorded	138
Ending Balance	2,292
Series C Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning Balance	0
Exchange of shares - Series A to Series C	60,776
Accretion of discount related to issuance costs	333
Dividends recorded	3,916
Ending Balance	$ 65,025

STOCKHOLDERS' DEFICIT - Pending Home Solutions Transaction (Details) - Home Solutions $ / shares in Units, shares in Thousands, $ in Millions	Jun. 16, 2016 USD ($) $ / shares shares
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 67.5
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares \| shares	3,750
Business Combination, Step Acquisition, Percentage of Common Stock Issuable	9.50%
Restricted Stock Units (RSUs) \| Tranche A
Business Acquisition [Line Items]
Business Acquisition, Share Price \| $ / shares	$ 4
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 3.1
Restricted Stock Units (RSUs) \| Tranche B
Business Acquisition [Line Items]
Business Acquisition, Share Price \| $ / shares	$ 5
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 4.0

DISCONTINUED OPERATIONS - Additional Information (Details) - PBM Services - USD ($) $ in Millions	Aug. 27, 2015	Oct. 20, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total cash consideration received in divestiture	$ 24.6
Reduction in consideration transferred		$ 1.0

DISCONTINUED OPERATIONS - Operating Results of Discontinued Operations (Details) - PBM Services - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 0	$ 15,466	$ 0	$ 32,790
Gross profit	0	3,722	0	7,358
Other operating expenses, net	(131)	3,647	(514)	9,689
Bad debt expense	0	(19)	0	(46)
Income (loss) before income taxes	131	94	514	(2,285)
Income tax provision	56	0	206	0
Total income (loss) from discontinued operations, net of income taxes	$ 75	$ 94	$ 308	$ (2,285)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring expense	$ 1,316	$ 4,398	$ 3,932	$ 7,861
Acquisition and integration expense	2,924	1,664	2,924	1,884
Change in fair value of contingent consideration	51	(93)	102	(72)
Total restructuring, acquisition, integration, and other expense, net	$ 4,291	$ 5,969	$ 6,958	$ 9,673

DEBT - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term Debt	$ 412,828
Less: Deferred financing costs	(14,181)	$ (15,863)
Total Debt	399,459	418,121
Less: Current portion	9,357	24,380
Long-term debt, net of current portion	390,102	393,741
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt	0	15,000
Term Loan Facilities
Debt Instrument [Line Items]
Long-term Debt	216,481	222,757
Long-term debt, net of current portion	166,300
2021 Notes
Debt Instrument [Line Items]
Long-term Debt	196,347	196,038
Capital Lease Obligations
Debt Instrument [Line Items]
Capital leases	$ 812	$ 189

DEBT - Additional Information (Details) - USD ($)	Jan. 31, 2014	Jun. 30, 2016	Dec. 31, 2015	Feb. 11, 2014	Jul. 31, 2013
Debt Instrument [Line Items]
Remaining principle amount of term loan		$ 390,102,000	$ 393,741,000
Senior credit facility \| Eurodollar
Debt Instrument [Line Items]
Minimum basis spread on debt	5.25%
Senior credit facility \| Base Rate
Debt Instrument [Line Items]
Minimum basis spread on debt	4.25%
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 70,400,000			$ 75,000,000.0
Effective interest rate		7.75%
Borrowing capacity subject to leverage test		$ 55,400,000
Outstanding letters of credit		$ 4,600,000
Term Loan Facilities
Debt Instrument [Line Items]
Effective interest rate		6.50%
Long-term loan facility payments		$ 3,100,000
Remaining principle amount of term loan		$ 166,300,000
Senior Unsecured 8.875% Notes
Debt Instrument [Line Items]
Face amount of debt instruments				$ 200,000,000.0
Stated rate on debt				8.875%
Debt discount				$ 5,000,000
Second Amendment \| Senior credit facility \| Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate	6.00%
Second Amendment \| Senior credit facility \| Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	5.00%
Second Amendment \| Second Lien Debt
Debt Instrument [Line Items]
Additional debt allowed under debt agreements					150,000,000.0
Second Amendment \| Unsecured Debt
Debt Instrument [Line Items]
Additional debt allowed under debt agreements					$ 250,000,000.0

DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	$ 412,828
Term Loan Facilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	216,481	$ 222,757
2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	196,347	$ 196,038
Markets for Identical Item (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	0
Markets for Identical Item (Level 1) \| Term Loan Facilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	0
Markets for Identical Item (Level 1) \| 2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	388,952
Significant Other Observable Inputs (Level 2) \| Term Loan Facilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	207,822
Significant Other Observable Inputs (Level 2) \| 2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	181,130
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	0
Significant Unobservable Inputs (Level 3) \| Term Loan Facilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	0
Significant Unobservable Inputs (Level 3) \| 2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt	$ 0

COMMITMENTS AND CONTINGENCIES (Details) - Civil Action $ in Millions	25 Months Ended
	Jan. 31, 2016 USD ($) payment
Loss Contingencies
Payments related to Settlement Agreements	$ 6.2
Settlement agreement accrual	$ 15.0
Interest rate, legal settlement	3.25%
Number of annual payments \| payment	3
Litigation settlement paid to Relator	$ 0.2

CONCENTRATION OF RISK (Details)	3 Months Ended		6 Months Ended
CONCENTRATION OF RISK (Details)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Customer Concentration Risk \| United Healthcare
Concentration Risk [Line Items]
Percentage of concentration risk	24.40%	25.40%	25.20%	25.90%
Customer Concentration Risk \| Medicare
Concentration Risk [Line Items]
Percentage of concentration risk	11.20%	10.40%	10.70%	10.80%
Product Concentration Risk \| Immune Globulin
Concentration Risk [Line Items]
Percentage of concentration risk	17.20%	16.00%	17.20%	15.80%

INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Federal	$ 0	$ 0	$ 0	$ 0
State	25	29	25	30
Total current	25	29	25	30
Federal	108	(16,816)	125	(15,188)
State	16	(3,134)	22	(2,835)
Total deferred	124	(19,950)	147	(18,023)
Total income tax expense (benefit)	$ 149	$ (19,921)	$ 172	$ (17,993)

INCOME TAXES - Reconciliation of the Income Tax Rate (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Tax benefit at statutory rate	$ (2,844)	$ (92,080)	$ (6,271)	$ (96,972)
State tax benefit, net of federal taxes	3	11	3	11
Valuation allowance changes affecting income tax provision	1,926	31,098	5,314	37,879
Goodwill impairment	0	40,977	0	40,977
Non-deductible transaction costs and other	1,064	73	1,126	112
Total income tax expense (benefit)	$ 149	$ (19,921)	$ 172	$ (17,993)

INCOME TAXES - Additional Information (Details) $ in Millions	Jun. 30, 2016 USD ($)
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 274.9
NOLs to be recorded in additional paid-in capital when realized	(18.0)
Net operating loss carryforwards subject to annual limitation	17.0
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 358.0

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		6 Months Ended
	May 08, 2014	May 07, 2013	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Par value of common stock (in dollars per share)			$ 0.0001		$ 0.0001		$ 0.0001
Equity Option
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense			$ 0.7	$ 1.2	$ 1.7	$ 3.1
Restricted Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense				0.1		0.3
Stock Appreciation Rights (SARs)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense				$ (0.1)	0.1	$ (0.6)
Market Based Cash Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense			$ (0.2)		$ 0.1
Employee Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)			750,000		750,000
Number of shares available for grant (in shares)			461,057		461,057
Share-based compensation expense					$ 0.1
Purchase price of common stock, percent		85.00%
Par value of common stock (in dollars per share)			$ 0.0001		$ 0.0001
Shares purchased on the open market for award (in shares)					288,943
2008 Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Adjustment to number of shares authorized (in shares)	2,500,000
Number of shares authorized (in shares)	9,355,000
Number of shares available for grant (in shares)			1,963,228		1,963,228